Marco Proietti

Dirigente medico

1: Proietti M, Lip GYH, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Boriani G; ESC-EORP Atrial Fibrillation General Long-Term Registry Investigators Group. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace. 2021 Feb 5;23(2):174-183. doi: 10.1093/europace/euaa274. PMID: 33006613.

2: Proietti M, Marzona I, Vannini T, Colacioppo P, Tettamanti M, Foresta A, Fortino I, Merlino L, Lip GYH, Roncaglioni MC. Impact of Liver Disease on Oral Anticoagulant Prescription and Major Adverse Events in Patients with Atrial Fibrillation. Eur Heart J Cardiovasc Pharmacother. 2020 Mar 4:pvaa015. doi: 10.1093/ehjcvp/pvaa015. Epub ahead of print. PMID: 32129845.

3: Proietti M, Marzona I, Vannini T, Tettamanti M, Fortino I, Merlino L, Basili S, Mannucci PM, Boriani G, Lip GYH, Roncaglioni MC, Nobili A. Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. Mayo Clin Proc. 2019 Dec;94(12):2427-2436. doi: 10.1016/j.mayocp.2019.06.012. Epub 2019 Oct 23. PMID: 31668449.

4: Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al- Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 Feb;208:123-131. doi: 10.1016/j.ahj.2018.09.017. Epub 2018 Nov 22. PMID: 30579505.

5: Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med. 2018 Nov;131(11):1359-1366.e6. doi: 10.1016/j.amjmed.2018.06.012. Epub 2018 Aug 26. PMID: 30153428.

6: Proietti M, Laroche C, Nieuwlaat R, Crijns HJGM, Maggioni AP, Lane DA, Boriani G, Lip GYH; EORP-AF General Pilot Registry; Euro Heart Survey on AF Investigators. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018 Sep;55:28-34. doi: 10.1016/j.ejim.2018.05.016. Epub 2018 May 16. PMID: 29778588.

7: Paciullo F, Proietti M, Bianconi V, Nobili A, Pirro M, Mannucci PM, Lip GYH, Lupattelli G; REPOSI Investigators. Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. Drugs Aging. 2018 Apr;35(4):365-373. doi: 10.1007/s40266-018-0532-8. PMID: 29564755.

8: Proietti M, Laroche C, Drozd M, Vijgen J, Cozma DC, Drozdz J, Maggioni AP, Boriani G, Lip GY; EORP-AF Investigators. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP- AF) General Registry. Am Heart J. 2016 Nov;181:83-91. doi: 10.1016/j.ahj.2016.08.011. Epub 2016 Aug 27. PMID: 27823697.

9: Violi F, Davì G, Proietti M, Pastori D, Hiatt WR, Corazza GR, Perticone F, Pignatelli P, Farcomeni A, Vestri AR, Lip GY, Basili S; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment- Collaborative Italian Study) STUDY Investigators. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost. 2016 Apr;115(4):856-63. doi: 10.1160/TH15-07-0612. Epub 2016 Jan 7. PMID: 26740316.

10: Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016 May;105(5):412-20. doi: 10.1007/s00392-015-0936-y. Epub 2015 Nov 2. PMID: 26525391.